Huberman Lab avatar

Dexa/Huberman Lab

Supported byHuberman Lab
Learn more
Published Jul 25, 2022

The Science & Treatment of Bipolar Disorder | Huberman Lab Podcast #82

Delve into the complexities of bipolar disorder with Andrew Huberman as he explores its types, neural mechanisms, and the innovative treatment approaches reshaping mental health care, including the time-honored use of lithium and emerging therapies like ketamine and rTMS.
Episode Highlights
Huberman Lab logo

Topics covered

Popular Clips

Questions from this episode

Episode Highlights

  • Lithium's Role

    Lithium has long been a cornerstone in treating bipolar disorder, dating back to its discovery in the 1940s. highlights the historical significance of lithium, noting its calming effects on guinea pigs and its subsequent application in human patients, which marked a breakthrough in psychiatric treatment 1. Despite its effectiveness, lithium's journey to widespread use was hindered by its inability to be patented, delaying its approval in the U.S. until 1970 2. Huberman emphasizes the importance of monitoring lithium levels due to its potential toxicity, underscoring the need for careful oversight during treatment 2.

    Lithium really stands as this kind of golden example of a treatment that works, at least in many individuals, prior to an understanding of the biological basis of the disease for which that treatment is needed.

    ---

    Today, lithium remains a low-cost yet effective option for many with bipolar disorder, though it requires careful management to mitigate side effects.

       

    New Therapies

    Innovative therapies are expanding the treatment landscape for bipolar disorder, offering new hope for patients. discusses the use of ketamine and repetitive transcranial magnetic stimulation (rTMS) as promising treatments for depressive episodes in bipolar disorder 3. While rTMS is minimally invasive and can target specific neural circuits, its availability is limited, and patients are advised to seek clinics associated with research institutions 3. Psilocybin, a psychedelic, is also being explored for its potential benefits in treating major depression, though its application to bipolar disorder remains unproven 4.

    Psilocybin is being explored as a clinical therapy in certain laboratory settings in particular, at Johns Hopkins School of Medicine.

    ---

    Despite the excitement surrounding these therapies, Huberman cautions that more research is needed to fully understand their efficacy and safety in treating bipolar disorder.

Related Episodes